NOTE 11 - NET LOSS PER SHARE	9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]
NOTE 11 - NET LOSS PER SHARE	NOTE 11 — NET LOSS PER SHARE Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and issuable during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The Company has 11,789,999 and 12,289,999 common stock options outstanding as of September 30, 2018 and 2017, respectively. These options are excluded from the calculation as they are antidilutive.

NOTE 11 - NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2018

NOTE 11 — NET LOSS PER SHARE

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and issuable during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.

The Company has 11,789,999 and 12,289,999 common stock options outstanding as of September 30, 2018 and 2017, respectively. These options are excluded from the calculation as they are antidilutive.

AngioGenex, Inc. 10-Q